Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study
Authors:
- 15 November 2017
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 32 (3) , 403-410
Abstract
Background: Palmoplantar psoriasis is a variant of psoriasis vulgaris which can severely impair quality of life.Objectives: The main objectives of this double‐blind, placebo‐controlled, randomized study were to assess the efficacy and impact on quality of life and work productivity of apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis.Methods: A total of 100 patients with moderate‐to‐severe palmoplantar psoriasis were randomized to either apremilast 30 mg bid or placebo for 16 weeks. At Week 16, all patients received apremilast 30 mg bid until Week 32. The primary endpoint was the proportion of patients who achieved a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0/1 at Week 16.Results: There was no significant difference in the proportion of patients who achieved a PPPGA of 0/1 at Week 16 between patients randomized to apremilast (14%) and placebo (4%; P = 0.1595). After 32 weeks of treatment with apremilast, 24% of patients achieved a PPGA of 0/1. In addition, apremilast was superior to placebo in achieving Palmoplantar Psoriasis Area Severity Index (PPPASI) 75 (apremilast: 22%; placebo: 8%; P = 0.0499), in improving PPPASI (apremilast: −7.4 ± 7.1; placebo: −3.6 ± 5.9; P = 0.0167), Dermatology Life Quality Index score (apremilast: −4.3 ± 5.1; placebo: −0.8 ± 4.5; P = 0.0004) and in reducing activity impairment (apremilast: −11.0 ± 22.3; placebo: 2.5 ± 25.5; P = 0.0063).Conclusion: Despite the absence of a significant difference between apremilast and placebo in proportion of patients achieving a PPPGA of 0/1, the presence of significant differences observed for several secondary endpoints suggests that apremilast may have a role in the treatment of moderate‐to‐severe palmoplantar psoriasis.Keywords
Funding Information
- AbbVie
- Amgen
- Boehringer Ingelheim
- Celgene
- Eli Lilly and Company
- GlaxoSmithKline
- LEO Pharma Research Foundation
- Merck
- Novartis
- Pfizer
- Regeneron Pharmaceuticals
- Valeant Pharmaceuticals International
- Abbott Fund
- DUSA Pharmaceuticals
- Novo Nordisk
- Sanofi
This publication has 18 references indexed in Scilit:
- Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized studyJournal of the European Academy of Dermatology and Venereology, 2012
- Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasisJournal of Dermatological Treatment, 2012
- Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and FeetArchives of Dermatology, 2011
- Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled studyJournal of the European Academy of Dermatology and Venereology, 2011
- A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patientsJournal of the European Academy of Dermatology and Venereology, 2009
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot psoriasisJournal of the American Academy of Dermatology, 2007
- Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled studyBritish Journal of Dermatology, 2001
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993
- Measurement of health statusControlled Clinical Trials, 1989